The Company and Basis of Presentation (Details) $ / shares in Units, $ in Millions			1 Months Ended	12 Months Ended
	Jan. 18, 2024 USD ($) $ / shares shares	Jan. 02, 2024 USD ($)	Aug. 31, 2019 patient	Dec. 31, 2020 product
Collaborations with Third Parties
Products approved | product				2
Estimated number of study patients | patient			14,000
First milestone payment		$ 100.0
Time required to pay cash portion		15 days
Second milestone payment		$ 25.0
Commitment Offering
Collaborations with Third Parties
Issued stock (in shares) | shares	56,700,000
Price per share (in dollars per share) | $ / shares	$ 1.50
Proceeds from stock offering, net	$ 90.7
Estimated offering expenses	$ 7.1
Over-Allotment Option
Collaborations with Third Parties
Issued stock (in shares) | shares	8,505,000
Option period	30 days
Minimum
Collaborations with Third Parties
Aggregate payment agreement		$ 125.0